Estimation of current share value9 Jan 2026 18:42
Asked GPT to give a realistic current valuation of the share price - tbh not sure how accurate it is but was curious.
Estimated Realistic Current Share Value (not price target):
👉 Approximately £0.30 – £0.60 per share in the absence of a confirmed partnership or Phase 3 plan.
What Would Meaningfully Change This Valuation?
Catalysts that could drive the share price higher:
• A partner deal with significant upfront payments or milestones.
• A defined Phase 3 study design and funding.
• Strong additional Phase 2 data (24–48-week efficacy).
• Clear commercial strategy (e.g., indications beyond IPF).
Scenario A — Successful Phase 2b (strong efficacy/safety)
• Markets typically reward Phase 2b success with a meaningful de-risking valuation boost.
• If zelasudil shows a clear, statistically significant benefit on FVC (forced vital capacity) and a clean safety profile, investors would price in a higher probability of Phase 3 success.
• Estimated range: ~£0.60 – £1.00 per share
With Phase 3 success, orphan exclusivity, and a commercial partner, the effective valuation could rise further as risk discounts fall and commercial upside is factored in.
Estimated range (post-Phase 3 success):
👉 £1.50 – £3.00+ per share
Bullish but Less Likely — Blockbuster / acquisition scenario
If zelasudil:
• Secures multiple indications beyond IPF (e.g., broader ILDs, combinations),
• Attracts a major pharma acquisition offer,
• Or demonstrates best-in-class competitive profile,
then valuations in biotech sometimes reach £3–£6+ per share, depending on deal terms and market conditions.
Makes interesting reading and if it reaches those kind of levels I’m sure we will all be happy to wait.
Lots of different scenarios, lots of ifs, buts and good luck. Tbh more importantly it could make a lot of people’s life’s so much more comfortable if successful despite the share price.
GLTA us long term holders and have a great weekend.
Sign In
Follow the stocks
